The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of biologics in addition to chemotherapy in the treatment of elderly Medicare patients with stage IV metastatic colon cancer.
C. Daniel Mullins
Consultant or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Eisai; Genentech; GlaxoSmithKline; Janssen; Mitsubishi; Novartis; Pfizer; Sanofi
Honoraria - Bayer
Research Funding - Bayer; FDA; NHLBI; NIA; NPC; PCORI; Pfizer; Sanofi
Fenghao Wang
Research Funding - Bayer
Kaloyan A. Bikov
Research Funding - Bayer
Brian S. Seal
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Nader Hanna
Honoraria - Bayer